Funding and Investment

SAN MARINO, CA - June 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.

Rexin-G(TM) is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-G(TM) seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.

Rexin-G recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.

In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which - by improving both the survival and the quality of life - provide cancer patients with more quality time."

More information: http://www.epeiusbiotech.com



Send2Press® is the originating wire service for this story.